Showing posts with label stem cells. Show all posts
Showing posts with label stem cells. Show all posts

Monday, 14 July 2025

Ask the doctors: Stem cells being researched to help with Type 1 diabetes

From spokesman.com

By Eve Glazier, M.D., and Elizabeth Ko, M.D.

Dear Doctors: I have Type 1 diabetes. I try to stay healthy and keep my blood sugar under control, but it feels like a fight every day. I read there’s a study using stem cells for a cure. Are there any updates? Does it seem like this might lead to a treatment?

Dear Reader: Type 1 diabetes is a chronic autoimmune disease. The immune system mistakenly targets and destroys beta cells in the pancreas. These cells are mainly responsible for producing insulin, the hormone crucial to glucose metabolism. Without enough insulin, the body is unable to keep blood glucose within a healthy range. Ways to manage blood sugar in these cases include injectable insulin, a carefully curated diet and healthy lifestyle choices.

Introduced in 1922, injectable insulin revolutionized diabetes treatment. Before that, life expectancy with the disease was just a few years. Today, even with the benefit of insulin, people with diabetes are at an increased risk of developing serious complications, including cardiovascular disease, nerve damage, kidney disease and eye damage. As you point out, the vigilance required to manage blood sugar can be both daunting and tiring. That brings us to your question.

Stem cells are what is known as undifferentiated cells. That means they have not yet developed a specific function, like muscle, bone or nerve cells. Because stem cells are like a blank slate, they can develop into other types of specialized cells. They can also self-renew. These unique qualities have made stem cells the focus of research into treatment for a wide range of diseases, including Type 1 diabetes.

In the clinical trial you asked about, participants were infused with stem cells “taught” to behave like beta cells. It was a small study with just 17 patients, but the preliminary results were encouraging. One participant’s body began to produce insulin and release it in response to blood sugar fluctuations. On the other hand, because these stem cell infusions introduce foreign tissue into the body, they require antirejection drugs. These drugs can cause side effects that can be hard to tolerate. Several participants dropped out of the study due to the adverse effects.

Many readers have asked for information about upcoming clinical trials into this line of research. Earlier this spring, the researchers announced they are moving on to the next expanded phase of research. As with all clinical trials, the parameters for participation are quite specific. In this case, the study is recruiting people with Type 1 diabetes who also have severe episodes of hypoglycaemia or have impaired awareness of hypoglycaemia. Due to the antirejection drugs, it’s important to remember there is also an element of risk.

The 27 locations of upcoming trials include cities in Illinois, Florida, California, Maryland, Texas, Massachusetts, Wisconsin and Pennsylvania. Trials in Canada and Europe are scheduled as well. For more details, visit clinicaltrials.gov and search for VX-880.

https://www.spokesman.com/stories/2025/jul/12/ask-the-doctors-stem-cells-being-researched-to-hel/

Tuesday, 13 May 2025

Understanding the Potential of Stem Cell Therapy for Diabetes Type 2

From healthline.com/health

Stem cell therapy is an emerging treatment for type 2 diabetes. Although it’s not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research.

Stem cells are special human cells that can become many different types of cells. Because of this special property, doctors are investigating the potential of stem cell therapy to treat many conditions.

People with type 2 diabetes don’t make an adequate amount of insulin to manage their blood sugar. Stem cell therapy may potentially allow people with type 2 diabetes to start producing more insulin again and reduce the need for medications.

The effectiveness and safety of stem cell therapy for treating diabetes are still under investigation, but some early studies have found promising results. 

Stem cell therapy involves taking stem cells from your body or another human’s to help regenerate damaged tissues.

Stem cells can be collected from foetal and adult tissues, such as:

  • fat tissue
  • umbilical cord
  • bone marrow
  • placenta

The diabetes epidemic remains one of the biggest health crises in the United States. Roughly 1 in 10Trusted Source people in the United States has diabetes, with the majority having type 2.

Researchers continue looking for new treatment options, and stem cell therapy has emerged as a promising option. Its use in humans is still being investigated, and more research is needed to assess its long-term effectiveness and safety accurately.

According to the authors of a 2025 letter to the editor, their team identified 143 diabetes stem cell therapy clinical trials worldwide from 2000 to 2024. Of these, 19 trials were ongoing.

Research on type 2 diabetes

Most research to date has examined stem cell therapy as a treatment for type 1 diabetes.

In 2008, a team of researchers recruited a small group of 25 people with type 2 diabetes for a phase 1 clinical trial examining the effectiveness of stem cell therapy combined with hyperbaric oxygen treatment. The researchers found that all measured markers, such as fasting glucose levels and insulin requirement, improved at a one-year follow-up.

Since then, more studiesTrusted Source have continued to find evidence that stem cell therapy may potentially improve blood sugar management and reduce the need for diabetes medications.

Further ongoing trials have also shown that stem cell therapy may help improve diabetic complications such as:

Modern research

In 2024Trusted Source, researchers reported a ground-breaking case of a 25-year-old woman with type 1 diabetes who started producing insulin within three months of receiving a stem cell transplant, effectively reversing her diabetes.

The results of current trials for type 2 diabetes look promising. Future research will focus on analysing long-term results and safety in larger groups.

Many clinical trials are currently underway. For instance, one clinical trial that’s currently recruiting is examining the effectiveness of stem cell therapy for treating type 2 diabetes that hasn’t responded to other treatments.

A phase II clinical trial that isn’t yet in the recruiting phase is examining the effectiveness and safety of a type of stem cell therapy that involves taking cells from your own body.

Treatment for type 2 diabetes typically consists of making lifestyle changes and sometimes taking medications. Commonly prescribed medications include:

These medications help improve your blood sugar management, but they need to be taken continuously to be effective. Stem cell therapy is an attractive alternative since it can potentially be curative after one treatment.

Stem cell therapy is still an experimental treatment. Researchers are continuing to see who might make a good candidate. For now, researchers may offer it as an experimental treatment for people who haven’t responded to other treatments.

Researchers are continuing to examine the safety of stem cell therapy for type 2 diabetes. Some concern is that it could encourage tumour formation.Trusted Source

Side effects reported in clinical trials included:

Improvements in blood sugar management have been reported in as little as weeks. For example, in a 2024 case study, researchers observed improvements in a 59-year-old man with severe diabetes complications within 2 weeks.

Studies consistently showTrusted Source improvements in blood sugar management, but larger studies are needed to understand the actual success rate.

Stem cell therapy for type 2 diabetes is still under investigation. In the United States, thousands of clinicsTrusted Source have appeared offering unlicensed and unproven stem cell therapies.

The FDA hasn’t yet approved stem cell therapies for diabetes.

Stem cell therapy isn’t yet available for treating type II diabetes in the United States. Because it’s not approved for use, it’s also not covered by insurance.

To get a rough idea of the cost, in one study, researchers estimated that the average price of stem cell therapy for diabetes might range from $5,000 to $50,000.

Little research examines the long-term effectiveness of stem cell therapy for diabetes. Most current studies have had follow-ups shorter than 1-2 years. Although it shows a lot of promise, more research is needed to judge long-term results accurately.

Can you still have traditional treatment during or after stem cell therapy?

Some people seem to reduce their need for medications or can stop taking medications altogether after stem cell therapy.

Stem cell therapy is being investigated as a potential treatment for type 2 diabetes. In theory, it may allow the body to produce more insulin to better regulate blood sugar levels.

Stem cell therapy isn’t yet FDA-approved in the United States for treating diabetes, but researchers continue examining its safety and effectiveness. The field of stem cell therapy is expanding rapidly, so it’s likely that many more studies will be completed in the next few years.

https://www.healthline.com/health/stem-cell-for-diabetes-type-2#stem-cell-therapy

Friday, 4 October 2024

How Stem Cells Reverse Diabetes For The First Time in History

From tecscience.tec.mx

A 25-year-old woman −with type 1 diabetes− began generating her own insulin three months after receiving a reprogrammed stem cell transplant 

For the first time in history, a multidisciplinary team of scientists managed to reverse type 1 diabetes in a 25-year-old patient, who received a reprogrammed stem cell transplant and less than three months later she started producing her own insulin.

She is the first human with type 1 diabetes to be treated using cells that were extracted from her own body. The results of his case were published on the specialized site Cell and the success of the procedure is already considered a milestone for modern medicine. 

The paper, signed by 35 scientists from various Chinese institutions, explains that the analysis was carried out over a period of one year and corresponds to “a first phase I clinical trial in humans that evaluates the viability of autologous transplantation of islets derived from chemically induced pluripotent stem cells (CiPSC islets) under the anterior rectum abdominal sheath for the treatment of type diabetes 1.”

What Does It Mean that Stem Cells Can Reverse Diabetes?

This stem cell transplant that has successfully reversed type 1 diabetes in a Chinese patient represents a major step forward in the treatment of this disease, which along with type 2 diabetes, is considered a chronic condition affecting more than 500 million people worldwide. 

According to the World Health Organization (WHO), diabetes “is a chronic metabolic disease characterized by elevated blood glucose (or blood sugar) levels, which over time leads to serious damage to the heart, blood vessels, eyes, kidneys and nerves.”

“The most common is type 2 diabetes, which occurs when the body becomes insulin resistant or does not produce enough insulin, while type 1 diabetes −once known as juvenile diabetes or insulin− dependent diabetes is a chronic condition in which the pancreas produces little or no insulin on its own,” adds WHO.

In both cases, patients require a special diet that restricts their sugar intake and they depend on insulin treatments for survival. They also need constant medical check-ups, which entails a huge expense for both individuals and their families, as well as for public health systems. Therefore, finding a cure for diabetes can transform the lives of millions of people.

For the specific case of the Chinese patient, the paper details: “she achieved sustained insulin independence starting 75 days post-transplantation. The patient’s time-in-target glycaemic range increased from a baseline value of 43.18% to 96.21% by month 4 post-transplantation, accompanied by a decrease in glycated haemoglobin, an indicator of long-term systemic glucose levels at a non-diabetic level.”

The study adds that “thereafter, the patient presented a state of stable glycaemic control, with time-in-target glycaemic range at >98% and glycated haemoglobin at around 5%. At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities.”

Although the woman has chosen to remain anonymous, it is known that she lives in Tianjin, China, is 25 years old and recently gave a telephone interview to Nature magazine in which she said: “I can eat sugar now… I enjoy eating everything, especially hotpot.”

                                                  3D illustration showing human stem cells floating in the veins. (Photo: Getty Images)

Are There Any Other Studies to Support this Finding?

While this is the first study to reverse type 1 diabetes in a human, Nature explains that this study “follows results from a separate group in Shanghai, China, who reported in April that they had successfully transplanted insulin-producing islets into the liver of a 59-year-old man with type 2 diabetes. The islets were also derived from reprogrammed stem cells taken from the man’s own body, and he has since stopped taking insulin.”

This study was published under the title “Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue” and details that the man had been diagnosed with this disease 25 years ago, but in 2017 he had a kidney transplant that worsened his health, leaving him dependent on several daily insulin injections.

According to the research, the patient received a stem cell transplant in July 2021 and 11 weeks later he no longer needed insulin injections. The study also noted that one year after the treatment, his islet cells function was restored and his kidney function was normal.

In this respect, Nature points out that there are previous investigations where “islet transplants can treat the disease, but there aren’t enough donors to meet the growing demand, and recipients must use immune-suppressing drugs to prevent the body from rejecting the donor tissue”. However, these new studies have shown that “by using tissue made from a person’s own cells, researchers also hope to avoid the need for immunosuppressants.”

Where Does the Procedure that Supports this Finding Come From?

The two investigations that have managed to reverse type 1 and type 2 diabetes in two Chinese patients, published this 2024, are based on a stem cell reprogramming technique that was developed more than 20 years ago by Japanese researcher Shinya Yamanaka at Kyoto University.

However, Nature notes that cell biologist Deng Hongkui of Beijing University, along with a group of Chinese researchers, modified this technique and “instead of introducing proteins that trigger gene expression, as Yamanaka had done, they exposed the cells to small molecules.”

By modifying this process, the Chinese scientists conducted a first test in which they “extracted cells from three people with type 1 diabetes and reverted them to a pluripotent state, from which they could be moulded into any type of cell in the body.”

Initially, scientists used chemically induced pluripotent stem cells (iPS) to generate 3D islet clusters, but tested their safety in mouse and primate cells. The 59-year-old patient’s research and the 25-year-old patient’s research are therefore among the first clinical trials in humans.

About the case of the 25-year-old patient whose transplant was performed in June 2023, the operation lasted less than half an hour and “she was injected with the equivalent of approximately 1.5 million islets into her abdominal muscles.”

Previously, islets had been injected into the liver in other procedures, but the cells could not be seen there. So the researchers decided to place them in the abdomen to monitor them  through magnetic resonance imaging and, if necessary, remove them.

Is this Stem Cell Treatment a Cure For Diabetes?

The authors of the research say that these are “promising results“, but warn that “more clinical studies evaluating CiPSC islet transplantation in type 1 diabetes are warranted.”

It is worth mentioning that the patient was already receiving immunosuppressants for a previous liver transplant, so scientists could not assess whether iPS cells reduced the risk of rejection of the transplant.

Jay Skyler, an endocrinologist at the University of Miami, Florida who studies type 1 diabetes, said in an interview with Nature that “it must still be verified that a woman’s cells continue to produce insulin for up to five years before she is considered cured.”

Chinese scientists have mentioned that “the results of two other participants are also very positive and will reach the mark of a year in November, after which they hope to extend the trial to another 10 or 20 individuals”, however, although hopeful, the road to a definitive cure for this disease still seems long.

https://tecscience.tec.mx/en/biotechnology/stem-cells-reverse-diabetes/

Tuesday, 27 August 2024

Diabetes took over her life, until a stem cell therapy freed her

From washingtonpost.com

Scientists are making progress replacing the critical insulin-producing cells that are destroyed by the disease 

For years, Amanda Smith and her husband were jolted awake at night by a buzz-buzz-beep — an alarm warning that her blood sugar was too high or too low. She would reach for juice boxes stored in her nightstand or fiddle with her pump to release a bolus of insulin.


Smith, a 35-year-old nurse from London, Ontario, has Type 1 diabetes, which wipes out critical islet cells within the pancreas that produce insulin. Without them, Smith relied on vials of insulin from a pharmacy and constant vigilance to stay alive. “You have to pay attention to your diabetes, or you die.”


On Valentine’s Day 2023, doctors transplanted replacement islet cells, grown in a lab from embryonic stem cells, into a blood vessel that feeds Smith’s liver. By August, she no longer needed insulin. Her new cells were churning it out.

“I just feel normal again,” Smith said. “You didn’t realize how much of your life it took up — until it’s taking up none, now.”


Patients such as Smith must take immune-suppressing drugs to prevent their body from rejecting transplanted cells that produce insulin. (Jennifer Roberts for The Washington Post)

Smith is at the forefront of a medical experiment that seeks to treat the root cause of diabetes by replacing the cells the disease destroys. It’s a key step forward in the long quest to develop a cure for diabetes and a front-runner to finally deliver the sci-fi promise that has enveloped the stem cell field for more than two decades.


Stem cells have the remarkable ability to develop into any cell or tissue in the body, and scientists have long dreamed of harnessing their regenerative power to repair the harm done by disease or injury.


Smith is one of a dozen patients who have received a full dose of islet cells generated in a laboratory from stem cells. Eleven of the patients in the clinical trial drastically reduced taking insulin or stopped altogether, according to data presented at an American Diabetes Association meeting in June.

Despite the promise, the therapy developed by Vertex Pharmaceuticals remains in early stages, and many experts consider it a major step forward, not the finish line.

No one knows how long these cells will keep churning out insulin or whether the therapy is safe long-term until it is tested and followed up in more patients, who must take immune-suppressing drugs to prevent their body from rejecting the foreign cells. One patient died of an infection caused by a complication of sinus surgery, highlighting the risk of immunosuppressive medications, which were among the factors contributing to the patient’s death.


Scott Soleimanpour, director of the Michigan Diabetes Research Centre, was diagnosed with Type 1 diabetes when he was 5 years old and recalled that throughout his youth, doctors told him there would be a cure within a decade. Soleimanpour, now in his 40s, made a pact with his childhood self not to promise specific timelines to his patients. Still, he remains hopeful.


“It’s terrible to have diabetes, but this is the best time in the history of the planet to have diabetes, because we have these amazing technologies,” Soleimanpour said. “We haven’t reached the end of the road, but we’re on the journey. It’s okay to sit at this stage of the journey and say, ‘This is good. Let’s keep going.’”


An imperfect path forward


The quest to cure diabetes didn’t start with stem cells. In 1966, doctors performed the first whole pancreas transplant in a diabetic patient. It was major surgery, not a practical treatment for the roughly 2 million people with Type 1 diabetes in the United States.


But as the biology of the pancreas was unravelled, scientists began imagining a stripped down version. Within the pancreas are islets, clusters of cells that produce insulin and other hormones. Instead of transplanting the whole organ, scientists wondered, what if they could use islets harvested from organ donors?


James Shapiro, a transplant surgeon at the University of Alberta in Edmonton, began working on the problem in the 1980s.


“None of the experiments I did worked,” Shapiro recalled. “In the beginning, we could scarcely reverse diabetes in a rat.”


Shapiro continued to chip away at the challenges, and in 2000, he and colleagues reported that seven patients had been transplanted with islets from organ donors — and were able to stop using insulin. The procedure, called the Edmonton Protocol, electrified diabetes researchers. It was proof that cells could be replaced and the disease could be reversed.


“Then, the warts started to become apparent,” Soleimanpour recalled.


Repeat transplants were often needed, and most patients eventually required some insulin again. The immune-suppressing drugs can increase the risk of infections, cancer or other side effects. And the supply of islets was extremely limited.


More than a thousand transplants in the years since showed the approach can work. Last year, U.S. regulators approved an islet cell therapy from organ donors. But use of the treatment is far from mainstream.


After receiving replacement cells that produce insulin, Smith says, “I pray this gets to everyone. My life has changed.” (Jennifer Roberts for The Washington Post)

Body, heal thyself


Researchers looked to the field of stem cell research to solve the scarcity problem.

Unlike most of the body’s cells, embryonic stem cells — which are created from human embryos — can give rise to every tissue and organ in the body, from brain to muscle to insulin-producing islet cells found in the pancreas. In theory, scientists could create as many as needed, with far better control over quality and consistency.


Douglas Melton was a biologist focused on frog development at Harvard University when, in 1991, his infant son, Sam, was diagnosed with Type 1 diabetes. His daughter, Emma, would also be diagnosed with the condition. Melton shifted his focus to study how insulin-producing cells normally develop, in hopes that scientists could imitate the process to help patients.


Melton quickly ran into a hard scientific truth about stem cells: Yes, they can become any kind of cell, but only if they’re coaxed through the right steps, akin to making an elaborate recipe. His laboratory spent two decades trying to devise the right steps, ingredients and timing, a trial-and-error process that resulted in a “six-step education process” that takes weeks.


Felicia Pagliuca had been working in cancer biology at the University of Cambridge when she met Melton at a seminar and was inspired to join his laboratory, drawn by the idea “that you could, instead of trying to kill cells to cure a disease, just use the cell itself as a building block of life — as a medicine,” Pagliuca said. “Especially the idea you could make these cells from scratch in the laboratory.”


To test their lab-grown cells, scientists put them in a dish with glucose and an indicator that changed colour in the presence of insulin. After many experiments, they saw a flash of blue, a sign they had finally gotten the recipe right.


In 2014, they published those results and founded Semma Therapeutics, which was later acquired by Vertex Pharmaceuticals for $950 million. Semma was named after Melton’s now grown-up children, aimed at moving a laboratory breakthrough into the real world.


‘My life has changed’


For Amanda Smith, diabetes wasn’t a manageable illness. It haunted her days and clouded her future. A family member lost a limb to the disease.


Smith had a particularly difficult time anticipating “lows,” when her blood sugar would drop. Once she’d realize it was happening, it was too late — “You just feel like death, you’re so weak you can’t move, you feel nauseous. And then you know: It’s do or die.” In trying to reverse the low, she might eat too many carbs, causing her blood sugar to spike. “You feel like a slug.”


As a child, she would remind her mom, who also has Type 1 diabetes, to check her sugars. Then she began to hear her own family do the same to her. Smith’s daughter Draya, now 9, would borrow her mom’s cellphone to play games but be interrupted by the alerts. “Check your sugars,” Draya would remind her, vowing to become a doctor and develop a cure.


Smith looks back on the quiet of the past year — no buzzers, no alarms — with a bit of wonder. Her medical team feels much the same.


“It’s amazing to see what it’s like, living with diabetes and six months later, essentially not having it,” said Trevor Reichman, surgical director of the Pancreas Transplant Program at the University of Toronto. Andrea Norgate, a nurse who works with him, interjected: “It’s the most exciting thing that’s happened in the world, ever, is probably more accurate.”


Three times a day, Smith takes pills to stop her immune system from destroying the foreign cells. She has had some side effects — early on, she got canker sores, and she’s careful around sick people. But for Smith, that’s manageable compared with the roller coaster and health risks of diabetes.


For the treatment to become safer and accessible to more patients, including young children, the next step is to find ways to protect the cells from the immune system.


Irl Hirsch, an endocrinologist at the University of Washington who has diabetes and has consulted for Vertex, recalled that before he started medical school in 1980, he worked for a famous endocrinologist, Paul Lacy, who was pursuing transplants in rodents to cure diabetes.

“What he told everybody is: We’d be doing these cell transplants in humans in five years. Everybody believed it,” Hirsch said. “That didn’t happen, and the big problem has been the whole issue of [immune] rejection and the need for immunosuppression. It was the problem in 1980, and it’s the problem now.”


Scientists aren’t waiting to tackle that problem. Vertex is testing a method of encapsulating the cells in a bioengineered device. The company is also using gene-editing techniques to make cells “hypoimmune,” or invisible to the immune system. Other researchers are creating stem cells from individual patients and coaxing those to become islet cells. Because the immune system won’t see those cells as foreign, it could reduce the amount of immunosuppression needed.


Trading one horrible disease for long-term immunosuppression gives many clinicians pause, but many patients and advocates are impatient. Today’s diabetes technologies are lifesaving but imperfect. The risks of infection must be weighed, but so must the risk of “having a heart attack 15 years before your peers, going blind and losing your kidneys,” said Aaron Kowalski, president of Breakthrough T1D, a research and advocacy organization.


Smith credits her insulin pump with keeping her alive but was elated to banish it to the back of a kitchen cabinet. She no longer has to plan her life around her illness.


“I pray this gets to everyone,” Smith said. “My life has changed.”


https://www.washingtonpost.com/health/2024/08/26/diabetes-stem-cell-therapy-insulin-success-story/